Barrington Research Reiterates Integra LifeSciences Outperform, $50 PT

Loading...
Loading...
Barrington Research reiterated its Integra LifeSciences
IART
Outperform rating and $50 price target in a research report published today. In the report, Barrington Research states, "We are reiterating our OUTPERFORM rating and $50 target following IART's Q4/11 results based on the organic and inorganic growth opportunities in each of IART's end markets." Shares of Integra LifeSciences were trading at $31.77 at the time of posting, up 1.92% from Monday's market close.
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationAnalyst Ratingsintegra lifesciences
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...